<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632524</url>
  </required_header>
  <id_info>
    <org_study_id>R68</org_study_id>
    <nct_id>NCT04632524</nct_id>
  </id_info>
  <brief_title>Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection</brief_title>
  <acronym>Anesthesia</acronym>
  <official_title>Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anesthesia for toxic goiter removal is a challenging because of of hemodynamic instability&#xD;
      especially during induction, intubation, manipulations of the gland, after removal of the&#xD;
      gland and during emergence. So, hemodynamic stability is required all through the operation&#xD;
      and even in the first 12 hours of the postoperative period to protect against complications&#xD;
      e.g., hypertension, tachycardia, myocardial ischemia, bleeding and thyrotoxic crisis.Mg&#xD;
      sulphate used in blunting pressor response during laryngoscopy and intubation. Also it was&#xD;
      used in controlled hypotension technique. Also it was reported in decreasing postoperative&#xD;
      nausea, vomiting, shivering and postoperative complications compared to controlled group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and Methods:&#xD;
&#xD;
      After obtaining the approval of the Ethical Committee number (R68) of Al Fayoum University&#xD;
      Hospitals and written informed consent from the patients, sixty (60) patients ASA ǀ &amp;ǁ&#xD;
      patients of both sex aging 20-70 years (with primary or secondary thyrotoxic goiter and will&#xD;
      be presented for thyroidectomy) will be allocated into one of two groups: Group (M) n=30 will&#xD;
      receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance&#xD;
      dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the&#xD;
      surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist&#xD;
      and the person who will collect the data will be blinded for the prepared solution. The&#xD;
      solution will be prepared by an expert anesthesia nurse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>sixty (60) patients ASA ǀ &amp;ǁ patients of both sex aging 16-78 years (with primary or secondary thyrotoxic goiter and will be presented for thyroidectomy) will be allocated into one of two groups: Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The patients were randomly allocated by a computer-generated table into one of two study groups. The randomization sequence was concealed in opaque sealed envelopes. The envelopes were opened by the study investigators just after recruitments and admission to the operation room.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure intraoperative</measure>
    <time_frame>5 minutes after induction of anesthesia</time_frame>
    <description>Mean arterial blood pressure measurement in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation intraoperative</measure>
    <time_frame>5 minutes after induction of anesthesia</time_frame>
    <description>SPO2 Measurement as percentage (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate intraoperative</measure>
    <time_frame>5 minutes after induction of anesthesia</time_frame>
    <description>HR intraoperative beats per minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure postoperative</measure>
    <time_frame>10minutes after extubation</time_frame>
    <description>Mean arterial blood pressure measurement mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate postoperative</measure>
    <time_frame>10 minutes after extubation</time_frame>
    <description>Heart Rate measurement by beats per minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation postoperative</measure>
    <time_frame>10 minutes after extubation</time_frame>
    <description>Spo2 measured as percentage %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation score post operative</measure>
    <time_frame>1 hour post operative</time_frame>
    <description>Sedation score frome 0 point awake and alert to 4 non arousable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale postoperative(hrs)</measure>
    <time_frame>4 hours post operative</time_frame>
    <description>A scale for measuring pain from 0 no pain up to 10 worst unbearable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opoid consumption intraoperative</measure>
    <time_frame>10 minutes after induction of anesthesia</time_frame>
    <description>Total dose calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Mg level at the beginning of operation</measure>
    <time_frame>10 minutes after induction of anesthesia</time_frame>
    <description>Blood sample for measuring mg serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opoid consumption postoperative</measure>
    <time_frame>4 hours post operative</time_frame>
    <description>Total dose calculated postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Mg level at the end of operation</measure>
    <time_frame>10 minutes befor extubation</time_frame>
    <description>Blood sample for measuring mg serum level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Haemodynamic Stability</condition>
  <arm_group>
    <arm_group_label>MgSO4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSO4</intervention_name>
    <description>Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.</description>
    <arm_group_label>MgSO4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients ASA ǀ &amp;ǁ&#xD;
&#xD;
          2. patients of both sex&#xD;
&#xD;
          3. Aging from 20-70years&#xD;
&#xD;
          4. Pstients with primary or secondary thyrotoxic goiter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major hepatic disease&#xD;
&#xD;
          2. renal disease.&#xD;
&#xD;
          3. Cardiac dysfunction e.g. (heart Failure).&#xD;
&#xD;
          4. Uncontrolled hypertension&#xD;
&#xD;
          5. Advanced Ischemic heart diseases.&#xD;
&#xD;
          6. Known allergy to Mg So4.&#xD;
&#xD;
          7. Morbid obesity &amp; pregnancy.&#xD;
&#xD;
          8. History of neuromuscular diseases.&#xD;
&#xD;
          9. cerebrovascular diseases.&#xD;
&#xD;
         10. Diabetic neuropathy.&#xD;
&#xD;
         11. patients receiving magnesium. supplementations.&#xD;
&#xD;
         12. Mental retardation&#xD;
&#xD;
         13. Patients on antiepileptic treatment&#xD;
&#xD;
         14. patients antipsychotics.&#xD;
&#xD;
         15. Hug goiter with retrosternal extension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atef</name>
      <address>
        <city>Fayoum</city>
        <zip>63512</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atef Mohamed Mahmoud, Lecture</last_name>
      <phone>01003973883</phone>
      <email>dr.atef.khalil@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Atef Mohamed Mahmoud, Lecturer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Alessandro Bacuzzi, Gianlorenzo Dionigi, Andrea Del Bosco, Giovanni Cantone, Tommaso Sansone, Erika Di Losa, Salvatore Cuffari. Anaesthesia for thyroid surgery: Perioperative management. International Journal of Surgery (2008);6: S82-S85. Sang-Hawn Do. Magnesium: a versatile drug for anesthesiologists. Korea J Anesthesiology 2013; 65 (1):4-8. Tramer MR, Shneider j, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology 1996; 84:340-7. Ryu JH, Sohn IS, Do SH. Controlled hypotension for middle ear surgery: a comparison between remifentanil and magnesium sulphate. Br J Anaesth 2009; 103: 490-5.</citation>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University Hospital</investigator_affiliation>
    <investigator_full_name>Atef Mohamed Sayed mahmoud</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Thyrotoxic goiter</keyword>
  <keyword>heamodynamics</keyword>
  <keyword>magnesium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goiter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Email inquiry</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

